探索重新使用的德福洛胺的潜力:弥合挑战和新的配方机会
Soumyadip Mukherjee1, Akhila Reddy1, Nikita Dutta1
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, India.
Nanomedicine (London, England)
|July 23, 2025
概括
德费洛克萨 (DFO) 药物输送挑战被新型载体克服,增强其用于治疗神经退行性疾病,癌症和铁亡的使用. 对DFO的研究和临床应用显著增加,突出了其治疗多功能性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物输送系统 药物输送系统
- 纳米技术 纳米技术
背景情况:
- 德费洛克萨甲基酸盐 (DFO) 面临的挑战包括药理动力学不佳 (半衰期低,分布有限) 和不良反应,阻碍临床使用.
- 新的药物载体系统已经出现,以减轻DFO的局限性,提高其接受度和治疗潜力.
研究的目的:
- 审查DFO制定和战略的进展情况.
- 要突出DFO日益扩大的治疗应用和研究兴趣.
主要方法:
- 在过去的18年里,在主要的科学数据库 (ScienceDirect,Nature,Wiley,ACS) 中进行了全面的文献搜索.
- 来自clinicaltrials.gov的临床试验数据和来自谷歌专利的专利申请的分析.
主要成果:
- 对新型DFO配方,如纳米颗粒,微粒和纳米纤维的研究显著增加.
- 自2020年以来,临床试验申请翻了一番,自2011年以来,专利申请增加了320%.
- 在治疗阿尔茨海默氏症,帕金森症,癌症,伤口愈合和铁死症方面,DFO的有效性已被证明.
结论:
- 新型药物输送系统成功解决了DFO的药理动力学和安全问题.
- DFO表现出了显著的多功能性,具有越来越大的潜力作为一种超越其传统应用的重用治疗剂.
相关概念视频
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28


